Cost-effectiveness of the addition of sintilimab as a first-line therapy for locally advanced or metastatic oesophageal squamous cell carcinoma: a Chinese healthcare system perspective

Table 1 Parameters of the various function distribution types

Treatment Strategy	Curve types	Function distribution type	AIC	BIC	Shape	Scale
Sin-Che	PFS	Weibull	1338.55	1346.13	1.42380	0.02685
		Exponential	1368.25	1372.04
		Log-normal	1304.72	1312.3	2.2031	0.8583
		Log-logistic	1310.59	1318.17	8.850	1.986
	OS	Weibull	1234.92	1242.5	1.52592	0.00889
		Exponential	1261.99	1265.78
		Log-normal	1236.56	1244.14	2.8852	1.0120
		Log-logistic	1229.09	1236.67	17.136	1.846
Pla-Che	PFS	Weibull	1397.31	1404.92	1.50328	0.04319
		Exponential	1450.93	1454.74
		Log-normal	1377.75	1385.36	1.7436	0.7917
		Log-logistic	1377.78	1385.39	2.209	5.807
	OS	Weibull	1524.31	1531.92	1.47603	0.01616
		Exponential	1558.06	1561.86
		Log-normal	1548.11	1555.72	2.5192	1.0221
		Log-logistic	1525.61	1533.22	12.337	1.858

ISSN: 2191-1991